MedTrace Logo

A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome

NCT04141969 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-12

No results posted yet for this study

Summary

This study will determine the effectiveness of a nutraceutical in treating the lingering effects of Lyme Disease after antibiotic treatment.

Conditions

  • Post-Lyme Disease Syndrome (PLDS)

Interventions

DIETARY_SUPPLEMENT

RLP

RLP nutraceutical

OTHER

Placebo

Inert brown powder

Sponsors & Collaborators

  • Optimal Health Research

    lead OTHER

Principal Investigators

  • Dr Osguthorpe, ND · Optimal Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2020-12-31
Completion
2021-03-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141969 on ClinicalTrials.gov